• Mirta Diez, Lucrecia M Burgos, Rocío C Baro Vila, and Mariano N Benzadón.
• Instituto Cardiovascular de Buenos Aires, Argentina. E-mail: mdiez@icba.com.ar.
• Medicina (B Aires). 2023 Jan 1; 83 (1): 748174-81.

IntroductionThere is growing evidence that telemonitoring (TM) in heart failure (HF) seems to improve their outcome. TM platforms have not been designed and evaluated in Argentina. The objective was to evaluate the feasibility, acceptability, usability and preliminary efficacy of a HF TM platform.MethodsAn open-label, paired pilot trial was conducted with a single-group intervention model. HF patients were included in an outpatient clinic in January 2021. A 24-hour 7-day TM platform was designed. The primary endpoint at 30 days was feasibility, acceptability, and usability.ResultsTwenty patients were included, mean age 62 ± 10 years; 542 parameter loads were analyzed. Self-perception related to health status compared to baseline was "slightly" or "markedly better" in 60% of patients, and in 75% "agree" or "totally agree" that TM improves patient care. In 80%, the loading of parameters did not interfere with their daily activities. The total mean pharmacological adherence prior to the TM intervention was 6.8 ± 1.3 and 7.7 ± 0.4 afterward (p = 0.019), with no differences found in the self-care scales.ConclusionThe TM of patients with HF seems to be feasible, with an adequate degree of acceptability. A significant increase in the total adherence rate was reduced, raising a hypothesis of potential benefit to be evaluated in a larger sample.

13 keywords...

hide…